To assess whether melittin–dKLA can reduce M2-like TAMs in tumor tissue, single cells from tumor tissues were harvested, and the numbers of F4/80+CD86+ M1 and F4/80+CD206+ M2-like TAMs in CD45+ leukocytes were measured by flow cytometry. This evidence concerns the gene CD86 and neoplasm.